Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PBI 1402

Drug Profile

PBI 1402

Alternative Names: PBI-1402

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProMetic Life Sciences
  • Developer Liminal BioSciences; ProMetic Life Sciences
  • Class Chemoprotectants; Colony-stimulating factors
  • Mechanism of Action Colony stimulating factor stimulants; Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Anaemia
  • No development reported Kidney disorders

Most Recent Events

  • 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
  • 22 Sep 2015 Phase-I/II development was completed for Anaemia in Canada and Eastern Europe
  • 18 Oct 2010 PBI 1402 licensed to Allist Pharmaceuticals in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top